CVE:NVH

Novoheart Competitors

C$0.53
+0.01 (+1.92 %)
(As of 11/20/2020)
Add
Compare
Today's Range
C$0.52
Now: C$0.53
C$0.53
50-Day Range
C$0.53
MA: C$0.53
C$0.53
52-Week Range
C$0.26
Now: C$0.53
C$0.72
Volume23,066 shs
Average Volume33,593 shs
Market CapitalizationC$99.98 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Novoheart (CVE:NVH) Vs. PLI, MDNA, EMC, NEPT, IMV, and RVX

Should you be buying NVH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Novoheart, including ProMetic Life Sciences (PLI), Medicenna Therapeutics (MDNA), Emblem (EMC), Neptune Wellness Solutions (NEPT), IMV (IMV), and Resverlogix (RVX).

ProMetic Life Sciences (TSE:PLI) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for ProMetic Life Sciences and Novoheart, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Novoheart0000N/A

Valuation and Earnings

This table compares ProMetic Life Sciences and Novoheart's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95

Novoheart has lower revenue, but higher earnings than ProMetic Life Sciences. Novoheart is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProMetic Life Sciences and Novoheart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
NovoheartN/AN/AN/A

Novoheart (CVE:NVH) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Valuation & Earnings

This table compares Novoheart and Medicenna Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60

Medicenna Therapeutics has lower revenue, but higher earnings than Novoheart. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Novoheart, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and Medicenna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoheartN/AN/AN/A
Medicenna TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Novoheart and Medicenna Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novoheart0000N/A
Medicenna Therapeutics0000N/A

Summary

Novoheart beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Novoheart (CVE:NVH) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Novoheart and Emblem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423,500.00236.08$-7,168,358.00C($0.04)-13.95
Emblem$5.71 million43.02$-24,806,020.00($0.19)-9.89

Novoheart has higher earnings, but lower revenue than Emblem. Novoheart is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Novoheart and Emblem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novoheart0000N/A
Emblem0000N/A

Profitability

This table compares Novoheart and Emblem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoheartN/AN/AN/A
EmblemN/AN/AN/A

Summary

Novoheart beats Emblem on 3 of the 5 factors compared between the two stocks.

Neptune Wellness Solutions (TSE:NEPT) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Profitability

This table compares Neptune Wellness Solutions and Novoheart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness SolutionsN/AN/AN/A
NovoheartN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Neptune Wellness Solutions and Novoheart, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
Novoheart0000N/A

Neptune Wellness Solutions currently has a consensus target price of C$4.63, suggesting a potential upside of 214.63%. Given Neptune Wellness Solutions' higher possible upside, equities analysts clearly believe Neptune Wellness Solutions is more favorable than Novoheart.

Valuation & Earnings

This table compares Neptune Wellness Solutions and Novoheart's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness SolutionsC$52.78 million4.61C$-223,415,550.00C($1.35)-1.09
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95

Novoheart has lower revenue, but higher earnings than Neptune Wellness Solutions. Novoheart is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Neptune Wellness Solutions beats Novoheart on 4 of the 7 factors compared between the two stocks.

Novoheart (CVE:NVH) and IMV (TSE:IMV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings and Valuation

This table compares Novoheart and IMV's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87

Novoheart has higher revenue and earnings than IMV. Novoheart is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoheartN/AN/AN/A
IMVN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Novoheart and IMV, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novoheart0000N/A
IMV04002.00

IMV has a consensus price target of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher possible upside, analysts plainly believe IMV is more favorable than Novoheart.

Novoheart (CVE:NVH) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Valuation and Earnings

This table compares Novoheart and Resverlogix's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95
ResverlogixN/AN/AN/AC$0.0163.57

Resverlogix has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and Resverlogix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoheartN/AN/AN/A
ResverlogixN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Novoheart and Resverlogix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novoheart0000N/A
Resverlogix0000N/A

Summary

Resverlogix beats Novoheart on 2 of the 3 factors compared between the two stocks.


Novoheart Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
MDNA
Medicenna Therapeutics
0.5$4.82+0.6%C$254.99 millionN/A-15.60
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.47+8.2%C$243.28 millionC$52.78 million-1.09Gap Up
IMV logo
IMV
IMV
1.2$3.39+1.5%C$229.54 millionC$3,000.00-5.87
RVX
Resverlogix
0.7$0.89+2.2%C$208.25 millionN/A63.57Upcoming Earnings
News Coverage
FRX
Fennec Pharmaceuticals
0.5$7.85+2.9%C$204.12 millionC$170,000.00-8.21Gap Up
ONC
Oncolytics Biotech
1.2$3.80+4.7%C$200.52 millionN/A-6.79
ATE
Antibe Therapeutics
1.3$4.27+6.3%C$194.32 millionC$9.33 million-5.43Gap Down
HBP
Helix BioPharma
0.5$0.88+3.4%C$124.20 millionN/A-16.00
IPA
ImmunoPrecise Antibodies
0.4$11.63+5.0%C$123.03 millionC$17.18 million-54.35
ACST
Acasti Pharma
0.8$0.53+3.8%C$88.79 millionC$81,000.0015.59
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.60+1.7%C$65.67 millionC$11.64 million-11.76
SBM
Sirona Biochem
0.5$0.36+4.2%C$58.80 millionC$123,870.00-27.69
PMN
ProMIS Neurosciences
0.5$0.18+0.0%C$55.07 millionC$1,787.00-9.00Gap Down
COV
Covalon Technologies
0.6$1.55+3.2%C$37.44 millionC$23.84 million-6.51
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36
IGX
IntelGenx Technologies
0.9$0.53+1.9%C$30.87 millionC$1.54 million-6.54
QPT
Quest PharmaTech
0.8$0.11+4.8%C$21.76 millionC$38,871.000.16High Trading Volume
Gap Up
CZO
Ceapro
0.7$0.72+2.8%C$21.65 millionC$16.14 million21.82
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20+2.6%C$14.12 millionC$1.34 million-5.57High Trading Volume
GSD
Devonian Health Group
0.5$0.28+7.1%C$13.96 millionC$1.59 million-5.83Gap Down
PAS
Pascal Biosciences
0.6$0.08+6.3%C$12.70 millionN/A-3.64Gap Up
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.33+3.0%C$10.16 millionC$4.12 million30.00Gap Down
HEM
Hemostemix
0.6$0.34+1.5%C$9.07 millionN/A-2.02Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.69+3.5%C$4.48 millionN/A-1.19
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3N/AN/AC$0.00C$267.59 million51.46
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.